GUTS Stock Analysis: Buy, Sell, or Hold?
GUTS - Fractyl Health, Inc. Common Stock
$0.76
-0.02 (-2.04%)
âŧ
5d:
+15.77%
30d:
-1.15%
90d:
-16.0%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 10, 2026
0d
Get Alerted When GUTS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: GUTS is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: GUTS is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: GUTS is currently trading at $0.76, which is considered slightly high relative to its 30-day fair value range of $0.67 to $0.79.
Technical Outlook: Technically, GUTS is in a downtrend. Immediate support is located at $0.64, while resistance sits at $0.81.
Market Sentiment: GUTS scores 23/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $5.03 (+545.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GUTS is in a downtrend. Immediate support is located at $0.64, while resistance sits at $0.81.
Market Sentiment: GUTS scores 23/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $5.03 (+545.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$0.67 -
$0.79
Company Quality Score
36/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
42.1%
All Signals
- BEARISH: Weak technical setup (23/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 545.3% below Wall St target ($5.03)
- WARNING: Composite score 36/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.67 -
$0.79
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$0.64
Resistance Level
$0.81
Current Trend
Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.13
Wall Street Target
$5.03
(+545.3%)
Revenue Growth (YoY)
-57.1%
Share & Embed Analysis
Last updated: August 24, 2026 10:24 AM ET
Data refreshes hourly during market hours. Next update: 11:24 AM
Data refreshes hourly during market hours. Next update: 11:24 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GUTS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 58 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 54 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$88 | 40 SELL |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$52 | 42 HOLD |
